NEW YORK – Johnson & Johnson has offered to pay up to $5.5 billion to settle tens of thousands of lawsuits alleging that its talcum-based baby powder caused ovarian cancer and mesothelioma, the company announced Monday, in what would be one of the largest product liability settlements in US history.
The proposed settlement aims to finally close a years-long legal battle that has dogged the healthcare giant and exposed it to billions of dollars in jury verdicts. J&J has consistently maintained that its talc products are safe and do not cause cancer, but has faced mounting pressure from courts and plaintiffs.
Settlement structure
The $5.5 billion offer represents a significant increase from previous settlement attempts. J&J had previously attempted to resolve the litigation through a controversial bankruptcy strategy that would have capped its liability at a lower amount. Courts rejected that approach, clearing the way for the current settlement framework.
The company says the settlement will be funded through a combination of cash reserves and insurance proceeds. Payments to claimants would be tiered based on the severity of their illness, with higher compensation for those diagnosed with mesothelioma, a rare cancer linked to asbestos exposure, and metastatic ovarian cancer.
This proposed settlement represents a major step toward resolving a litigation that has cast a cloud over the company for nearly a decade. While we continue to believe the claims are not supported by science, we have concluded that resolving this matter is in the best interest of the company and its shareholders.
Johnson & Johnson statement
Legal context
The baby powder litigation began in earnest in the mid-2010s after studies suggested a possible link between talc use in the genital area and ovarian cancer. J&J faced more than 50,000 lawsuits across multiple state and federal courts, with several high-profile trials resulting in multimillion-dollar verdicts against the company.
Some of those verdicts were later reduced or overturned on appeal, but the cumulative legal pressure and the uncertainty of future trials created significant financial exposure. J&J stopped selling talc-based baby powder in the United States and Canada in 2020, switching to cornstarch-based alternatives.
Financial impact
The $5.5 billion settlement would eclipse many previous record product liability agreements. For context, the $20 billion national opioid settlement with major pharmaceutical distributors remains the largest multi-state settlement in US history, while individual product settlements of this magnitude are rare.
J&J reported more than $85 billion in annual revenue in its most recent fiscal year. The company has set aside reserves for the settlement, and the payout is expected to be structured over several years to minimize the impact on its balance sheet and dividend payments to shareholders.
Investor reaction
Wall Street reacted cautiously to the news. J&J shares rose modestly in early trading as investors welcomed the prospect of resolution after years of uncertainty. Analysts noted that removing the litigation overhang could improve the company’s risk profile and potentially lead to a re-rating of the stock.
However, some investors remain cautious. The settlement requires approval from a sufficient number of claimants to proceed. If too many plaintiffs opt out and pursue individual trials, J&J could still face significant legal exposure.
Outlook
The settlement now enters a claims period during which plaintiffs will decide whether to accept the offer or continue litigating. Legal experts expect the majority of claimants to accept, given the certainty of a payout versus the risks and delays of trial.
For J&J, closing the talc chapter would allow management to focus on its core pharmaceutical and medical device businesses, where the company is pursuing growth in oncology, immunology, and surgical robotics. The company also faces ongoing litigation related to its opioid marketing practices, though on a smaller scale than the talc cases.
The baby powder settlement, if finalized, would mark the end of one of the most protracted and closely watched product liability sagas in modern American corporate history.
discussion